Nebulizers – Medicare Advantage Policy Guideline
UnitedHealthcare? Medicare Advantage Policy Guideline
Nebulizers
Guideline Number: MPG211.07 Approval Date: June 8, 2022
Terms and Conditions
Table of Contents
Page
Policy Summary ............................................................................. 1
Applicable Codes .......................................................................... 2
Definitions ...................................................................................... 5
Questions and Answers ................................................................ 6
References ..................................................................................... 6
Guideline History/Revision Information ....................................... 7
Purpose .......................................................................................... 7
Terms and Conditions ................................................................... 8
Related Medicare Advantage Policy Guidelines ? Home Use of Oxygen ? KX Modifier
Related Medicare Advantage Coverage Summary ? Durable Medical Equipment (DME), Prosthetics,
Corrective Appliances/Orthotics (Non-Foot Orthotics), Nutritional Therapy and Medical Supplies Grid
Policy Summary
Overview
Nebulizers can be covered if the member's ability to breathe is severely impaired.
See Purpose
Lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma are characterized by airflow limitation that may be partially or completely reversible. Pharmacologic treatment with bronchodilators is used to prevent and/or control daily symptoms that may cause disability for persons with these diseases. These medications are intended to improve the movement of air into and from the lungs by relaxing and dilating the bronchial passageways. Beta adrenergic agonists are a commonly prescribed class of bronchodilator drug. They can be administered via nebulizer, metered dose inhaler, orally, or dry powdered inhaler.
Guidelines
For a DME item to be covered by Medicare, it must 1) be eligible for a defined Medicare benefit category, 2) be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member, and 3) meet all other applicable Medicare statutory and regulatory requirements. The "reasonable and necessary" criteria, based on Social Security Act ?1862(a)(1)(A) provisions, are defined by the following coverage indications, limitations and/or medical necessity.
A diagnosis code describing the condition which necessitates nebulizer therapy must be included on each claim for equipment, accessories, and/or drugs.
Nebulizers require a face-to-face encounter and a Written Order Prior to Delivery (WOPD).
Documentation Requirements - General
There are numerous CMS manual requirements, reasonable and necessary requirements, benefit category, and other statutory and regulatory requirements that must be met in order for payment to be justified. In the event of a claim review, a DMEPOS supplier must provide sufficient information to demonstrate that the applicable criteria have been met thus justifying payment. Refer to the LCD, NCD or other CMS Manuals for more information on what documents may be required.
Nebulizers
Page 1 of 8
UnitedHealthcare Medicare Advantage Policy Guideline
Approved 06/08/2022
Proprietary Information of UnitedHealthcare. Copyright 2022 United HealthCare Services, Inc.
See Article A55426 Standard Documentation Requirements for All Claims Submitted to DME MACs.
Applicable Codes
The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.
Coding Clarifications: *Compounded inhalation solutions will be denied as not reasonable and necessary. **There are no FDA-approved final products for these drugs hence the codes are invalid for claim submission.
HCPCS Code A7003 A7004 A7005 A7006 A7007 A7008 A7009 A7010 A7012 A7013 A7014 A7015 A7016 A7017 A7018 E0565 E0570 E0572 E0574 E0575 E0585 E1372 G0333 J2545
J7604*
J7605
J7606
Description Administration set, with small volume nonfiltered pneumatic nebulizer, disposable Small volume nonfiltered pneumatic nebulizer, disposable Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable Administration set, with small volume filtered pneumatic nebulizer Large volume nebulizer, disposable, unfilled, used with aerosol compressor Large volume nebulizer, disposable, prefilled, used with aerosol compressor (Non-covered) Reservoir bottle, non-disposable, used w/ large volume ultrasonic nebulizer (Non-covered) Corrugated tubing, disposable, used with large volume nebulizer, 100 feet Water collection device, used with large volume nebulizer Filter, disposable, used with aerosol compressor or ultrasonic generator Filter, non-disposable, used with aerosol compressor or ultrasonic generator Aerosol mask, used with DME nebulizer Dome and mouthpiece, used with small volume ultrasonic nebulizer Nebulizer, durable, glass or autoclavable plastic, bottle type, not used with oxygen Water, distilled, used with large volume nebulizer, 1000 ml Compressor, air power source for equipment which is not self- contained or cylinder driven Nebulizer, with compressor Aerosol compressor, adjustable pressure, light duty for intermittent use Ultrasonic/electronic aerosol generator with small volume nebulizer Nebulizer, ultrasonic, large volume (Non-covered) Nebulizer, with compressor and heater Immersion external heater for nebulizer Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary Pentamidine isethionate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 300 mg Acetylcysteine, inhalation solution, compounded product, administered through DME, unit dose form, per gram Arformoterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 15 micrograms Formoterol fumarate, inhalation solution, FDA approved final product, non-compounded, administered through DME, unit dose form, 20 micrograms
Nebulizers
Page 2 of 8
UnitedHealthcare Medicare Advantage Policy Guideline
Approved 06/08/2022
Proprietary Information of UnitedHealthcare. Copyright 2022 United HealthCare Services, Inc.
HCPCS Code J7607* J7608 J7609* J7610* J7611 J7612 J7613 J7614 J7615* J7620 J7622* J7624* J7626 J7627* J7628* J7629* J7631 J7632* J7633** J7634* J7635* J7636* J7637* J7638* J7639
Description Levalbuterol, inhalation solution, compounded product, administered through DME, concentrated form, 0.5 mg
Acetylcysteine, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per gram
Albuterol, inhalation solution, compounded product, administered through DME, unit dose, 1 mg
Albuterol, inhalation solution, compounded product, administered through DME, concentrated form, 1 mg
Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 1 mg
Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 0.5 mg
Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 1 mg
Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 0.5 mg
Levalbuterol, inhalation solution, compounded product, administered through DME, unit dose, 0.5 mg
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, noncompounded, administered through DME
Beclomethasone, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Betamethasone, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Budesonide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, up to 0.5 mg
Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg
Bitolterol mesylate, inhalation solution, compounded product, administered through DME, concentrated form, per milligram
Bitolterol mesylate, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Cromolyn sodium, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 milligrams
Cromolyn sodium, inhalation solution, compounded product, administered through DME, unit dose form, per 10 milligrams
Budesonide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per 0.25 mg
Budesonide, inhalation solution, compounded product, administered through DME, concentrated form, per 0.25 milligram
Atropine, inhalation solution, compounded product, administered through DME, concentrated form, per milligram
Atropine, inhalation solution, compounded product, administered through DME, unit dose form, per mg
Dexamethasone, inhalation solution, compounded product, administered through DME, concentrated form, per milligram
Dexamethasone, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Dornase alfa, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per milligram
Nebulizers
Page 3 of 8
UnitedHealthcare Medicare Advantage Policy Guideline
Approved 06/08/2022
Proprietary Information of UnitedHealthcare. Copyright 2022 United HealthCare Services, Inc.
HCPCS Code J7640* J7641* J7642* J7643* J7644 J7645* J7647* J7648** J7649** J7650* J7657* J7658** J7659** J7660* J7667* J7668** J7669 J7670* J7676* J7677 J7680* J7681* J7682 J7683*
Description Formoterol, inhalation solution, compounded product, administered through DME, unit dose form, 12 micrograms
Flunisolide, inhalation solution, compounded product, administered through DME, unit dose, per milligram
Glycopyrrolate, inhalation solution, compounded product, administered through DME, concentrated form, per milligram
Glycopyrrolate, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Ipratropium bromide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per milligram
Ipratropium bromide, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Isoetharine HCL, inhalation solution, compounded product, administered through DME, concentrated form, per milligram
Isoetharine HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per mg
Isoetharine HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per mg
Isoetharine HCL, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Isoproterenol HCL, inhalation solution, compounded product, administered through DME, concentrated form, per milligram
Isoproterenol HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per mg
Isoproterenol HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per mg
Isoproterenol HCL, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligrams
Metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per 10 mg
Metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 milligrams
Metaproterenol sulfate, inhalation solution, compounded product, administered through DME, unit dose form, per 10 milligrams
Pentamidine isethionate, inhalation solution, compounded product, administered through DME, unit dose form, per 300 mg
Revefenacin inhalation solution, FDA-approved final product, non-compounded, administered through DME, 1 mcg
Terbutaline sulfate, inhalation solution, compounded product, administered through DME, concentrated form, per milligram
Terbutaline sulfate, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, per 300 milligrams
Triamcinolone, inhalation solution, compounded product, administered through DME, concentrated form, per milligram
Nebulizers
Page 4 of 8
UnitedHealthcare Medicare Advantage Policy Guideline
Approved 06/08/2022
Proprietary Information of UnitedHealthcare. Copyright 2022 United HealthCare Services, Inc.
HCPCS Code J7684*
J7685*
J7686
J7699 K0730 Q0513 Q0514 Q4074
Description Triamcinolone, inhalation solution, compounded product, administered through DME, unit dose form, per milligram Tobramycin, inhalation solution, compounded product, administered through DME, unit dose form, per 300 milligrams Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg NOC drugs, inhalation solution administered through DME Controlled dose inhalation drug delivery system Pharmacy dispensing fee for inhalation drug(s); per 30 days Pharmacy dispensing fee for inhalation drug(s); per 90 days Iloprost, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, up to 20 micrograms
Modifier KO KP KQ KX
Description Single drug unit dose formulation First drug of a multiple drug unit dose formulation Second or subsequent drug of a multiple drug unit dose formulation Requirements specified in the medical policy have been met
Place of Service Code
Description
As Defined By DME Supplier Manual
01
Pharmacy
04
Homeless Shelter
09
Prison/Correctional Facility
12
Home
13
Assisted Living Facility
14
Group Home
16
Temporary Lodging
33
Custodial Care Facility
54
Intermediate Care Facility/Mentally Retarded
55
Residential Substance Abuse Treatment Facility
56
Psychiatric Residential Treatment Center
65
End Stage Renal Disease (ESRD) Treatment Facility (valid POS for Parenteral Nutrition Therapy)
Diagnosis Code Nebulizers: Diagnosis Code List
Definitions
Compound Inhalation Solution: A product produced by a pharmacy that is not an FDA-approved manufacturer and involves the mixing, combining or altering of ingredients for an individual patient. Compounded drugs are not considered interchangeable with FDA-approved products.
Nebulizers
Page 5 of 8
UnitedHealthcare Medicare Advantage Policy Guideline
Approved 06/08/2022
Proprietary Information of UnitedHealthcare. Copyright 2022 United HealthCare Services, Inc.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- nebulizer order template centers for medicare medicaid services
- coding guidelines for certain respiratory care services may 2020
- nebulizers and inhalation drugs cgs medicare
- durable medical equipment dme billing codes and reimbursement rates
- nebulizers medicare advantage policy guideline
- ohio medicaid dme procedure codes requiring provider licensure or
- pulmozyme billing codes
- durable medical equipment dme oxygen and respiratory equipment dura
- nebulizer appendix a centers for medicare medicaid services
- nebulizer treatment policy procedure
Related searches
- meridian medicare advantage providers
- meridian medicare advantage plans
- meridian medicare advantage michigan
- compare 2018 medicare advantage plans
- meridian medicare advantage plans michigan
- aarp medicare advantage plan
- aarp medicare advantage member sign in
- medicare advantage eligibility requirements
- medicare advantage formulary 2019
- aarp medicare advantage formulary 2020
- bcbs medicare advantage formulary 2019
- best 2020 medicare advantage plan